Douglas S. Ingram
Douglas S. Ingram's purchase track record
Douglas S. Ingram has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/3/2023 | SRPT | $2.00M | +55.5% | +71.3% | +17.6% |
| 11/17/2021 | SRPT | $2.00M | +0.3% | -14.1% | -16.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Sarepta Shares New DM1 Data at Oligonucleotide Meeting. Sarepta Therapeutics presented new preclinical data for SRP-1003, a treatment for myotonic dystrophy type 1, at the 2026 Oligonucleotide Therapeutics Society Annual Meeting. The data indicated robust knockdown of pathogenic DMPK RNA in the nucleus. This update highlights the company's ongoing research efforts, while the stock currently trades near its 52-week low with a volume spike.
Transaction History
| ARWR | ▲ Buy | Grant | 7,819 | $0 | 12/16/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 50,000 | $0 | 12/7/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 50,000 | $0 | 12/7/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 73,001 | $0 | 12/7/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 269,542 | $0 | 12/7/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 96,541 | $0 | 12/7/2025 | View on chart |
| ARWR | ▲ Buy | Grant | 38,396 | $771K | 2/6/2025 | View on chart |
| SRPT | ▲ Buy | Open Market | 10,081 | $792K | 11/3/2023 | View on chart |
| SRPT | ▲ Buy | Open Market | 200 | $16K | 11/3/2023 | View on chart |
| SRPT | ▲ Buy | Open Market | 11,060 | $881K | 11/3/2023 | View on chart |
| SRPT | ▲ Buy | Open Market | 3,884 | $312K | 11/3/2023 | View on chart |
| SRPT | ▲ Buy | Open Market | 25,026 | $2.0M | 11/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value
Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value. Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.